In recent years

under the dual pressure of national pharmaceutical policy adjustments and intensified market competition

the pharmaceutical manufacturing industry has been facing severe challenges

with financial risks being particularly prominent. As a representative enterprise in the industry

Xiangxue Pharmaceutical's financial risk situation has attracted much attention. Taking Xiangxue Pharmaceutical as the research object

this paper analyzes the enterprise's financial risk status from four dimensions: financing risk

investment risk

operational risk

and cash flow risk. It points out that the enterprise has problems in financial risk prevention

such as insufficient response to policies

excessive investment expansion

irregular information disclosure

and imperfect internal control. Corresponding countermeasures are proposed

including strengthening capital management

optimizing business layout

improving the quality of information disclosure

and enhancing internal control. The purpose is to provide risk management and control references for Xiangxue Pharmaceutical and other pharmaceutical enterprises

and help enterprises achieve stable development.